Macrophage Migration Inhibitory Factor in Inflammasome Formation and Macrophage Recruitment by Cervical Squamous Cell Carcinoma Cells

Overview

Journal Oncol Lett

Specialty Oncology

Date 2025 Feb 13

PMID 39944790

Authors

Qianqian Zhang

Mengxin Wang

Suhui Wu

Affiliations

Soon will be listed here.

Abstract

Despite the demonstrated efficacy of immune checkpoint blockade therapies in various types of cancer, their efficacy in cervical cancer is limited. A crucial pro-inflammatory cytokine, macrophage migration inhibitory factor (MIF), is highly expressed in various types of cancers and contributes to tumor progression via the regulation of inflammatory responses and the tumor microenvironment. The present study aimed to explore the role of MIF in cervical squamous cell carcinoma (CSCC). Western blotting, reverse transcription-quantitative polymerase chain reaction, Cell-Counting Kit-8, flow cytometry and enzyme-linked immunosorbent assays were used to investigate the effects of MIF on CSCC progression and in the formation of inflammasomes using SiHa cells. Transcriptome and proteome sequencing were combined to screen for key effector proteins of MIF. Moreover, co-culture experiments were used to evaluate the roles of MIF and TSC22 domain family protein 3 (TSC22D3) as inflammatory tumor-promoting factors in macrophage recruitment and polarization induction. The results indicated that MIF was highly expressed in CSCC with lymph node metastasis, positively associated with cervical cancer stage, and associated with a poor prognosis. MIF was also found to promote the progression of CSCC cells and to be associated with inflammasome activation. Multi-omics screening results indicated that TSC22D3 may be an important MIF interacting factor. Moreover, MIF and TSC22D3 facilitated inflammasome activation, THP-1 cell migration and M2 polarization. Therefore, it is suggested that MIF and TSC22D3 may induce macrophage infiltration in cervical cancer lesions and affect the tumor microenvironment by polarizing macrophages toward the M2 phenotype, thereby promoting CSCC progression. The present study highlights the potential of the MIF-TSC22D3 axis as a novel therapeutic target, which could conceivably help to improve the efficacy of immunotherapy in the treatment of recurrent or metastatic cervical cancer.

References

Wang Q, Wei Y, Zhang J . Combined Knockdown of D-dopachrome Tautomerase and Migration Inhibitory Factor Inhibits the Proliferation, Migration, and Invasion in Human Cervical Cancer. Int J Gynecol Cancer. 2017; 27(4):634-642. DOI: 10.1097/IGC.0000000000000951. View

Locati M, Curtale G, Mantovani A . Diversity, Mechanisms, and Significance of Macrophage Plasticity. Annu Rev Pathol. 2019; 15:123-147. PMC: 7176483. DOI: 10.1146/annurev-pathmechdis-012418-012718. View

Cao X, Xu J . Insights into inflammasome and its research advances in cancer. Tumori. 2019; 105(6):456-464. DOI: 10.1177/0300891619868007. View

Barnett K, Li S, Liang K, Ting J . A 360° view of the inflammasome: Mechanisms of activation, cell death, and diseases. Cell. 2023; 186(11):2288-2312. PMC: 10228754. DOI: 10.1016/j.cell.2023.04.025. View

Chen W, Zheng R, Baade P, Zhang S, Zeng H, Bray F . Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66(2):115-32. DOI: 10.3322/caac.21338. View

Fu J, Schroder K, Wu H . Mechanistic insights from inflammasome structures. Nat Rev Immunol. 2024; 24(7):518-535. PMC: 11216901. DOI: 10.1038/s41577-024-00995-w. View

Bian Z, Gong Y, Huang T, Lee C, Bian L, Bai Z . Deciphering human macrophage development at single-cell resolution. Nature. 2020; 582(7813):571-576. DOI: 10.1038/s41586-020-2316-7. View

Monk B, Colombo N, Tewari K, Dubot C, Caceres M, Hasegawa K . First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826. J Clin Oncol. 2023; 41(36):5505-5511. DOI: 10.1200/JCO.23.00914. View

Zhao H, Wu L, Yan G, Chen Y, Zhou M, Wu Y . Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther. 2021; 6(1):263. PMC: 8273155. DOI: 10.1038/s41392-021-00658-5. View

10.

Yang H, Xia L, Chen J, Zhang S, Martin V, Li Q . Stress-glucocorticoid-TSC22D3 axis compromises therapy-induced antitumor immunity. Nat Med. 2019; 25(9):1428-1441. DOI: 10.1038/s41591-019-0566-4. View

11.

Jia X, Xi J, Tian B, Zhang Y, Wang Z, Wang F . The Tautomerase Activity of Tumor Exosomal MIF Promotes Pancreatic Cancer Progression by Modulating MDSC Differentiation. Cancer Immunol Res. 2023; 12(1):72-90. DOI: 10.1158/2326-6066.CIR-23-0205. View

12.

Basak U, Sarkar T, Mukherjee S, Chakraborty S, Dutta A, Dutta S . Tumor-associated macrophages: an effective player of the tumor microenvironment. Front Immunol. 2023; 14:1295257. PMC: 10687432. DOI: 10.3389/fimmu.2023.1295257. View

13.

Monk B, Tewari K, Dubot C, Caceres M, Hasegawa K, Shapira-Frommer R . Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2023; 24(4):392-402. DOI: 10.1016/S1470-2045(23)00052-9. View

14.

Wang L, Wang C, Tao Z, Zhu W, Su Y, Choi W . Tumor-associated macrophages facilitate oral squamous cell carcinomas migration and invasion by MIF/NLRP3/IL-1β circuit: A crosstalk interrupted by melatonin. Biochim Biophys Acta Mol Basis Dis. 2023; 1869(5):166695. DOI: 10.1016/j.bbadis.2023.166695. View

15.

Anderson N, Minutolo N, Gill S, Klichinsky M . Macrophage-Based Approaches for Cancer Immunotherapy. Cancer Res. 2020; 81(5):1201-1208. DOI: 10.1158/0008-5472.CAN-20-2990. View

16.

Kloosterman D, Akkari L . Macrophages at the interface of the co-evolving cancer ecosystem. Cell. 2023; 186(8):1627-1651. DOI: 10.1016/j.cell.2023.02.020. View

17.

Tsuchiya S, Yamabe M, Yamaguchi Y, Kobayashi Y, Konno T, Tada K . Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int J Cancer. 1980; 26(2):171-6. DOI: 10.1002/ijc.2910260208. View

18.

Ravichandran K, Heneka M . Inflammasomes in neurological disorders - mechanisms and therapeutic potential. Nat Rev Neurol. 2024; 20(2):67-83. DOI: 10.1038/s41582-023-00915-x. View

19.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

20.

Wu S, Lian J, Tao H, Shang H, Zhang L . Correlation of macrophage migration inhibitory factor gene polymorphism with the risk of early-stage cervical cancer and lymphatic metastasis. Oncol Lett. 2012; 2(6):1261-1267. PMC: 3406491. DOI: 10.3892/ol.2011.409. View